FDA Grants Orphan Drug Designation to AGMB-447 for Idiopathic Pulmonary Fibrosis
Currently, the drug is being evaluated in a phase 1 clinical trial to determine the safety and efficacy in patients.
Source: pharmacytimes.com
Phasei Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Phasei Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Phasei Study Today - Breaking & Trending Today
JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)
JJP Biologics has received a positive conclusion on the Clinical Trial Application assessment for a Phase I Study of a potential first-in-class anti-CD89 antagonist, JJP-1212 monoclonal antibody for
Source: finanznachrichten.de
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology Annual Meeting
NKGen Biotech, Inc. announced an online publication, titled ?Interim Analysis of a Phase I Study using Cryopreserved Non-genetically Modified Allogeneic Natural Killer Cells With Enhanced Cytotoxicity...
Source: marketscreener.com
Novartis Scemblix® shows superior major molecular response
MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for...
Source: globenewswire.com
Eisai's Commitment To Oncology Demonstrated By Clinical Data To Be Presented At ASCO Annual Meeting
LONDON, May 16 /PRNewswire/ -- Eisai Europe Ltd announced today that results from 9 clinical data abstracts about compounds in the company's oncology pipeline, product portfolio and preclinical oncology research have been accepted for presentation at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicag
Source: science20.com